– UK, Cambridge – Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the appointment of Ed Rayner to its Board as a Non-Executive Director.
About Edward Rayner
Ed Rayner has held several key analyst and portfolio management positions at leading research-led investment firms, including AMP Capital, Alliance Bernstein, UBS Asset Management, and JP Morgan Investment Management. He has worked across a broad range of sectors, including healthcare and technology, in addition to managing equity portfolios, running a research team, and launching a small company fund. More recently, Ed worked in biotech venture capital at Arix Bioscience and, in that role, represented the fund as a NED for various Life Sciences companies, including Pharmaxis, Depixus, and Simbec Orion Group. In his current role as a Healthcare Consultant for investment bank Panmure Gordon, he works with private Life Sciences companies to raise capital. He has an MA in Chemistry and an MSc in Management from Oxford University and is a Chartered Financial Analyst.
Ed Rayner commented: “I’m excited to join the Sphere Fluidics Board to support the Company as it accelerates its commercial roll out. The multi-disciplinary science and engineering teams have developed a ground-breaking suite of products that can make a huge difference to the success of drug development programmes.”
For more information: https://spherefluidics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.